You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長春高新(000661.SZ):取得思安信新冠疫苗(PIV-5載體)等相關技術在中國獨家許可權利
格隆匯 06-07 18:54

格隆匯6月7日丨長春高新(000661.SZ)公佈,公司及子公司長春百克生物科技股份公司(簡稱“百克生物”)擬與廣州思安信生物技術有限公司(簡稱“思安信”)就取得新型冠狀病毒疫苗(PIV-5載體)及針對新冠病毒突變株研發的疫苗(PIV-5載體)相關技術在中國大陸、香港、澳門及台灣地區(“許可區域內”)的獨家許可權利簽署《許可合作協議》。

長春高新將向思安信支付首付款0.35億元,長春高新和百克生物將分階段向思安信支付研發里程碑付款共計2.4億元,產品上市後長春高新將每年按相應銷售價格及銷量向思安信支付總限額5.65億元的銷售里程碑款項,上述付款合計8.4億元;同時產品上市後百克生物將每年按相應銷售價格及銷量向思安信支付一定比例的銷售額提成直至許可專利的專利授權有效期屆滿。

公司董事長馬驥在思安信擔任董事職務,公司董事、總經理安吉祥在思安信擔任監事職務,思安信為公司關聯方,該次交易構成關聯交易。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account